InspireMD Inc NSPR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NSPR is a good fit for your portfolio.
News
-
InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference
-
InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024
-
InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
-
InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th
-
InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System
-
InspireMD Receives CE Mark Recertification Under EU’s New Medical Device Regulation (MDR) Regulatory Framework
Trading Information
- Previous Close Price
- $2.32
- Day Range
- $2.25–2.34
- 52-Week Range
- $0.96–3.85
- Bid/Ask
- $2.24 / $2.70
- Market Cap
- $53.25 Mil
- Volume/Avg
- 10,931 / 38,119
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 8.92
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 66
- Website
- https://www.inspiremd.com
Comparables
Valuation
|
Metric
|
NSPR
|
SIBN
|
INSP
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 159.79 |
Price/Book Value | 1.26 | 3.93 | 12.40 |
Price/Sales | 8.92 | 4.52 | 11.27 |
Price/Cash Flow | — | — | 107.58 |
Price/Earnings
NSPR
SIBN
INSP
Financial Strength
|
Metric
|
NSPR
|
SIBN
|
INSP
|
|---|---|---|---|
Quick Ratio | 6.89 | 8.01 | 7.05 |
Current Ratio | 7.34 | 9.01 | 7.60 |
Interest Coverage | — | −13.52 | — |
Quick Ratio
NSPR
SIBN
INSP
Profitability
|
Metric
|
NSPR
|
SIBN
|
INSP
|
|---|---|---|---|
Return on Assets (Normalized) | −43.29% | −8.97% | 7.16% |
Return on Equity (Normalized) | −52.86% | −12.61% | 8.31% |
Return on Invested Capital (Normalized) | −53.49% | −11.78% | 5.07% |
Return on Assets
NSPR
SIBN
INSP
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Mqmrtplp | Lqcdpdd | $188.9 Bil | |
SYK
| Stryker Corp | Dkhkvnssvd | Tqwc | $129.0 Bil | |
MDT
| Medtronic PLC | Hgwqvtq | Vyrbk | $106.5 Bil | |
BSX
| Boston Scientific Corp | Qhtzsdgz | Pqdwb | $100.9 Bil | |
EW
| Edwards Lifesciences Corp | Brqztzcsrz | Blrxbv | $53.7 Bil | |
DXCM
| DexCom Inc | Rdmkpypk | Rryd | $51.9 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Tlfvqqgwp | Dwvy | $25.5 Bil | |
ALGN
| Align Technology Inc | Jypvhptn | Xmqgkgp | $24.7 Bil | |
PHG
| Koninklijke Philips NV ADR | Pzyhksbr | Dvpqls | $18.7 Bil | |
PODD
| Insulet Corp | Slcfwztqlg | Jhfcy | $12.3 Bil |